Home Newsfeeds Roth Capital Initiates Coverage On NEXTracker with Buy Rating, Announces Price Target of $45

Roth Capital Initiates Coverage On NEXTracker with Buy Rating, Announces Price Target of $45

Roth Capital analyst Philip Shen initiates coverage on NEXTracker (NASDAQ:NXT) with a Buy rating and announces Price Target of $45.

byBenzinga Newsdesk

March 6, 2023

1 minute read

Roth Capital analyst Philip Shen initiates coverage on NEXTracker (NASDAQ:NXT) with a Buy rating and announces Price Target of $45.

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment In Phase 3 REBUILD Study For INOpulse In Fibrotic Interstitial Lung Disease; Company Expects To Report Top-Line Results From This Study In Mid-2023

By Happy Mohamed

May 11, 8:32 AM

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today

BLPH

‘Election Risks And Potential Tariffs’ Among Other Geo-Political Issues Impacting Temu’s Parent PDD, Says Analyst: ‘Leading Many To Attach Zero Or Even Negative Value’

By Benzinga Neuro

May 28, 5:02 AM

The stock of PDD Holdings Inc, the parent company of Temu, is currently trading at its lowest level ever. This is despite the company's robust growth and performance in the e-commerce sector.

BABA

Franklin Electric’s Current Valuation Keeps This Analyst Patient; Seeks Better Entry Point

By Lekha Gupta

April 19, 1:44 PM

Oppenheimer analyst Bryan F. Blair initiated coverage on Franklin Electric Co Inc (NASDAQ:FELE) with Perform rating. The analyst commends the company’s fast-growing…

FELE

Movers
News

Why NextEra Energy Stock Is Down

By Erica Kollmann

June 11, 3:32 PM

NextEra Energy shares are trading lower Tuesday. The company reaffirmed its 2024-2026 EPS guidance and issued 2027 targets ahead of its Investor Day event. Here's a look at the details:

NEE

Roth Capital Initiates Coverage On NEXTracker with Buy Rating, Announces Price Target of $45

Related Posts

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment In Phase 3 REBUILD Study For INOpulse In Fibrotic Interstitial Lung Disease; Company Expects To Report Top-Line Results From This Study In Mid-2023

‘Election Risks And Potential Tariffs’ Among Other Geo-Political Issues Impacting Temu’s Parent PDD, Says Analyst: ‘Leading Many To Attach Zero Or Even Negative Value’

Franklin Electric’s Current Valuation Keeps This Analyst Patient; Seeks Better Entry Point

Why NextEra Energy Stock Is Down